{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:20:05Z","timestamp":1793146805076,"version":"4.5.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100005788","name":"Medical University of Vienna","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005788","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40263-026-01312-w","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T06:39:10Z","timestamp":1782715150000},"page":"1285-1294","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Impact of Omaveloxolone on Serum Lipids in Patients with Friedreich Ataxia: A 1-Year Real-World Analysis"],"prefix":"10.1007","volume":"40","author":[{"given":"Dominic","family":"Buchinger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Scherer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Dalos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2990-0243","authenticated-orcid":false,"given":"Ivan","family":"Milenkovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,29]]},"reference":[{"issue":"2","key":"1312_CR1","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1097\/NEN.0b013e31827e5762","volume":"72","author":"AH Koeppen","year":"2013","unstructured":"Koeppen AH, Mazurkiewicz JE. Friedreich ataxia: neuropathology revised. J Neuropathol Exp Neurol. 2013;72(2):78\u201390. https:\/\/doi.org\/10.1097\/NEN.0b013e31827e5762.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"10","key":"1312_CR2","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1001\/archneur.65.10.1296","volume":"65","author":"M Pandolfo","year":"2008","unstructured":"Pandolfo M. Friedreich ataxia. Arch Neurol. 2008;65(10):1296\u2013303. https:\/\/doi.org\/10.1001\/archneur.65.10.1296.","journal-title":"Arch Neurol"},{"issue":"7","key":"1312_CR3","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/S1474-4422(25)00175-9","volume":"24","author":"K Reetz","year":"2025","unstructured":"Reetz K, Lischewski SA, Dogan I, Didszun C, Pishnamaz M, Konrad K, et al. Friedreich\u2019s ataxia: a rare multisystem disease. Lancet Neurol. 2025;24(7):614\u201324. https:\/\/doi.org\/10.1016\/S1474-4422(25)00175-9.","journal-title":"Lancet Neurol"},{"issue":"2","key":"1312_CR4","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1017\/s031716710004395x","volume":"9","author":"D Blache","year":"1982","unstructured":"Blache D, Bouthillier D, Barbeau A, Davignon J. Plasma lipoprotein lipase and hepatic lipase activities in Friedreich\u2019s ataxia. Can J Neurol Sci. 1982;9(2):191\u20134. https:\/\/doi.org\/10.1017\/s031716710004395x.","journal-title":"Can J Neurol Sci"},{"issue":"4","key":"1312_CR5","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1017\/s0317167100023015","volume":"7","author":"YS Huang","year":"1980","unstructured":"Huang YS, Marcel YL, Vezina C, Barbeau A, Davignon J. Lecithin: cholesterol acyltransferase activity and fatty acid composition of erythrocyte phospholipids in Friedreich\u2019s ataxia. Can J Neurol Sci. 1980;7(4):429\u201334. https:\/\/doi.org\/10.1017\/s0317167100023015.","journal-title":"Can J Neurol Sci"},{"issue":"4 Suppl.","key":"1312_CR6","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1017\/s0317167100035198","volume":"11","author":"AC Nestruck","year":"1984","unstructured":"Nestruck AC, Huang YS, Eid K, Dufour R, Boulet L, Barbeau A, et al. Plasma cholesteryl sulfate in Friedreich\u2019s ataxia. Can J Neurol Sci. 1984;11(4 Suppl.):631\u20136. https:\/\/doi.org\/10.1017\/s0317167100035198.","journal-title":"Can J Neurol Sci"},{"issue":"9","key":"1312_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jlr.2022.100255","volume":"63","author":"D Wang","year":"2022","unstructured":"Wang D, Ho ES, Cotticelli MG, Xu P, Napierala JS, Hauser LA, et al. Skin fibroblast metabolomic profiling reveals that lipid dysfunction predicts the severity of Friedreich\u2019s ataxia. J Lipid Res. 2022;63(9):100255. https:\/\/doi.org\/10.1016\/j.jlr.2022.100255.","journal-title":"J Lipid Res"},{"issue":"2","key":"1312_CR8","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1002\/1531-8257(200003)15:2<294::aid-mds1013>3.0.co;2-d","volume":"15","author":"BM Ross","year":"2000","unstructured":"Ross BM, Eder K, Moszczynska A, Mamalias N, Lamarche J, Ang L, et al. Abnormal activity of membrane phospholipid synthetic enzymes in the brain of patients with Friedreich\u2019s ataxia and spinocerebellar atrophy type-1. Mov Disord. 2000;15(2):294\u2013300. https:\/\/doi.org\/10.1002\/1531-8257(200003)15:2%3c294::aid-mds1013%3e3.0.co;2-d.","journal-title":"Mov Disord"},{"issue":"2","key":"1312_CR9","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1002\/ana.25934","volume":"89","author":"DR Lynch","year":"2021","unstructured":"Lynch DR, Chin MP, Delatycki MB, Subramony SH, Corti M, Hoyle JC, et al. Safety and efficacy of omaveloxolone in Friedreich ataxia (MOXIe study). Ann Neurol. 2021;89(2):212\u201325. https:\/\/doi.org\/10.1002\/ana.25934.","journal-title":"Ann Neurol"},{"issue":"4","key":"1312_CR10","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1007\/s40120-025-00752-8","volume":"14","author":"S Perlman","year":"2025","unstructured":"Perlman S, Anheim M, Boesch S, Lewis JH, Lynch DR. Managing aminotransferase elevations in patients with Friedreich ataxia treated with omaveloxolone: a review and expert opinion on use considerations. Neurol Ther. 2025;14(4):1209\u201327. https:\/\/doi.org\/10.1007\/s40120-025-00752-8.","journal-title":"Neurol Ther"},{"issue":"3","key":"1312_CR11","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1007\/s40120-025-00749-3","volume":"14","author":"K Gunther","year":"2025","unstructured":"Gunther K, Profeta V, Keita M, Park C, Wells M, Sharma S, et al. Safety monitoring of omaveloxolone in Friedreich ataxia: results from one year of clinical treatment. Neurol Ther. 2025;14(3):1105\u201314. https:\/\/doi.org\/10.1007\/s40120-025-00749-3.","journal-title":"Neurol Ther"},{"issue":"11","key":"1312_CR12","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-025-13487-1","volume":"272","author":"SM Lima","year":"2025","unstructured":"Lima SM, Caltagirone M, Messina C, Quartetti U, Rini N, D\u2019Amico F, et al. Early experience on omaveloxolone in adult patients with Friedreich\u2019s ataxia: a real-world observational study. J Neurol. 2025;272(11):742. https:\/\/doi.org\/10.1007\/s00415-025-13487-1.","journal-title":"J Neurol"},{"key":"1312_CR13","volume-title":"Skyclarys (omaveloxolone): EPAR: product information","author":"European Medicines Agency","year":"2024","unstructured":"European Medicines Agency. Skyclarys (omaveloxolone): EPAR: product information. Amsterdam: European Medicines Agency; 2024."},{"issue":"3","key":"1312_CR14","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1001\/jamacardio.2021.5080","volume":"7","author":"AD Sniderman","year":"2022","unstructured":"Sniderman AD, Navar AM, Thanassoulis G. Apolipoprotein B vs low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol as the primary measure of apolipoprotein B lipoprotein-related risk: the debate is over. JAMA Cardiol. 2022;7(3):257\u20138. https:\/\/doi.org\/10.1001\/jamacardio.2021.5080.","journal-title":"JAMA Cardiol"},{"issue":"9","key":"1312_CR15","doi-asserted-by":"publisher","first-page":"641","DOI":"10.7326\/0003-4819-121-9-199411010-00002","volume":"121","author":"B Kinosian","year":"1994","unstructured":"Kinosian B, Glick H, Garland G. Cholesterol and coronary heart disease: predicting risks by levels and ratios. Ann Intern Med. 1994;121(9):641\u20137. https:\/\/doi.org\/10.7326\/0003-4819-121-9-199411010-00002.","journal-title":"Ann Intern Med"},{"key":"1312_CR16","first-page":"757","volume":"5","author":"J Millan","year":"2009","unstructured":"Millan J, Pinto X, Munoz A, Zuniga M, Rubies-Prat J, Pallardo LF, et al. Lipoprotein ratios: physiological significance and clinical usefulness in cardiovascular prevention. Vasc Health Risk Manag. 2009;5:757\u201365.","journal-title":"Vasc Health Risk Manag."},{"issue":"1","key":"1312_CR17","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1080\/13543784.2023.2173063","volume":"32","author":"V Profeta","year":"2023","unstructured":"Profeta V, McIntyre K, Wells M, Park C, Lynch DR. Omaveloxolone: an activator of Nrf2 for the treatment of Friedreich ataxia. Expert Opin Investig Drugs. 2023;32(1):5\u201316. https:\/\/doi.org\/10.1080\/13543784.2023.2173063.","journal-title":"Expert Opin Investig Drugs"},{"issue":"8","key":"1312_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/antiox12081491","volume":"12","author":"M Fuertes-Agudo","year":"2023","unstructured":"Fuertes-Agudo M, Luque-Tevar M, Cucarella C, Martin-Sanz P, Casado M. Advances in understanding the role of NRF2 in liver pathophysiology and its relationship with hepatic-specific cyclooxygenase-2 expression. Antioxidants (Basel). 2023;12(8):1491. https:\/\/doi.org\/10.3390\/antiox12081491.","journal-title":"Antioxidants (Basel)"},{"issue":"2","key":"1312_CR19","doi-asserted-by":"publisher","first-page":"90","DOI":"10.3164\/jcbn.13-92","volume":"54","author":"T Kamisako","year":"2014","unstructured":"Kamisako T, Tanaka Y, Kishino Y, Ikeda T, Yamamoto K, Masuda S, et al. Role of Nrf2 in the alteration of cholesterol and bile acid metabolism-related gene expression by dietary cholesterol in high fat-fed mice. J Clin Biochem Nutr. 2014;54(2):90\u20134. https:\/\/doi.org\/10.3164\/jcbn.13-92.","journal-title":"J Clin Biochem Nutr"},{"issue":"17","key":"1312_CR20","doi-asserted-by":"publisher","first-page":"3305","DOI":"10.1128\/MCB.00677-14","volume":"34","author":"PJ Meakin","year":"2014","unstructured":"Meakin PJ, Chowdhry S, Sharma RS, Ashford FB, Walsh SV, McCrimmon RJ, et al. Susceptibility of Nrf2-null mice to steatohepatitis and cirrhosis upon consumption of a high-fat diet is associated with oxidative stress, perturbation of the unfolded protein response, and disturbance in the expression of metabolic enzymes but not with insulin resistance. Mol Cell Biol. 2014;34(17):3305\u201320. https:\/\/doi.org\/10.1128\/MCB.00677-14.","journal-title":"Mol Cell Biol"},{"issue":"9","key":"1312_CR21","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1172\/JCI15593","volume":"109","author":"JD Horton","year":"2002","unstructured":"Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Investig. 2002;109(9):1125\u201331. https:\/\/doi.org\/10.1172\/JCI15593.","journal-title":"J Clin Investig"},{"issue":"2","key":"1312_CR22","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1194\/jlr.M700443-JLR200","volume":"49","author":"HJ Jeong","year":"2008","unstructured":"Jeong HJ, Lee HS, Kim KS, Kim YK, Yoon D, Park SW. Sterol-dependent regulation of proprotein convertase subtilisin\/kexin type 9 expression by sterol-regulatory element binding protein-2. J Lipid Res. 2008;49(2):399\u2013409. https:\/\/doi.org\/10.1194\/jlr.M700443-JLR200.","journal-title":"J Lipid Res"},{"issue":"8","key":"1312_CR23","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.3390\/antiox10081280","volume":"10","author":"YK Lin","year":"2021","unstructured":"Lin YK, Yeh CT, Kuo KT, Yadav VK, Fong IH, Kounis NG, et al. Pterostilbene increases LDL metabolism in HL-1 cardiomyocytes by modulating the PCSK9\/HNF1alpha\/SREBP2\/LDLR signaling cascade, upregulating epigenetic hsa-miR-335 and hsa-miR-6825, and LDL receptor expression. Antioxidants (Basel). 2021;10(8):1280. https:\/\/doi.org\/10.3390\/antiox10081280.","journal-title":"Antioxidants (Basel)."}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-026-01312-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-026-01312-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-026-01312-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T06:28:36Z","timestamp":1786948116000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-026-01312-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,29]]},"references-count":23,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1312"],"URL":"https:\/\/doi.org\/10.1007\/s40263-026-01312-w","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,29]]},"assertion":[{"value":"9 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ivan Milenkovic has received speaker honoraria from Biogen and Sanofi. Dominic Buchinger, Thomas Scherer, and Daniel Dalos have no conflicts of interest that are directly relevant to the content of this article.","order":1,"name":"Ethics","label":"Conflicts of Interest\/competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the local Ethics Committee of the Medical University of Vienna (EK Nr. 1995\/2025) and was conducted in accordance with the principles of the Declaration of Helsinki and its amendments.","order":2,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted retrospectively using data obtained for clinical purposes. In view of the retrospective design and use of fully anonymized data, informed consent to participate was not required.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The datasets generated and analyzed during the current study are available from the corresponding author upon reasonable request, owing to ethical restrictions and data protection regulations.","order":5,"name":"Ethics","label":"Data Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors contributed to the study conception and design. DB and IM performed data curation and dataset generation. Statistical analyses were performed by IM. The first draft of the manuscript was prepared by DB. Data interpretation and critical revision of the manuscript were performed by DB, DD, and TS. All the authors have reviewed and approved the final version of the manuscript.","order":7,"name":"Ethics","label":"Authors\u2019 Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}